European Pharmacopoeia Ph Eur Monograph Tablets 0478 Better Patched

aim to further align disintegration and dissolution tests across the Ph. Eur., USP, and JP. Policy Shift (2020)

While uniformity of mass indirectly assures content uniformity for potent drugs where the active substance constitutes a large proportion of the tablet, many modern drugs are highly potent (e.g., levothyroxine, digoxin). For such tablets, monograph 0478 mandates direct assay of 10 individual tablets. The acceptance value must be ≤15.0. This test is arguably the most important for patient safety, as it directly verifies that each patient receives the correct dose. european pharmacopoeia ph eur monograph tablets 0478 better

: Manufacturers must ensure tablets possess suitable mechanical strength to prevent crumbling or breaking during handling. This is typically verified through Friability (2.9.7) Resistance to Crushing (2.9.8) Subdivision of Scored Tablets aim to further align disintegration and dissolution tests

There it was. A hairline fracture, invisible to the naked eye, just above the paddle blade. At 75 rpm, the shaft would flex by less than a millimeter. But that millimeter was enough to create a micro-vortex that spun the disintegrating tablet away from the probe, making the dissolution appear slower.

For immediate-release tablets, the monograph requires that tablets disintegrate completely within a specified time (usually 15 minutes for uncoated tablets) in a physiological medium (water or simulated gastric fluid) at 37°C. Disintegration is a prerequisite for dissolution; if a tablet does not break apart, the active substance cannot be absorbed. This test guards against over-compression or excessive binding, which would render the tablet ineffective.